Several DNL inhibitors have exhibited their capacity to decrease IHTG levels in both MASLD individuals and those exhibiting features of metabolic syndrome—a cluster of characteristics that increases the risk of developing MASLD [54,90,91,92,93,95,96]. This evidence concerns the gene DNASE2 and metabolic dysfunction-associated steatotic liver disease.